26 mayo 2016 año - FDA announced required safety labeling changes for methadone and buprenorphine products when used by pregnant women for medication- assisted treatment (MAT) of opioid use disorder to ensure providers have complete information about the benefits and risks of these products. FDA approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence.
Añadido al timeline:
fecha:
26 mayo 2016 año
Ahora mismo
~ 9 years and 5 months ago